A Single-Arm Exploratory Study of NatureU Pelvic Health Pumpkin Seed in Women With Urinary Frequency and Leakage Symptoms
NUPHPS
A Single-Center, Open-Label, Single-Arm Exploratory Study of NatureU Pelvic Health Pumpkin Seed in Adult Women With Urinary Frequency and Urinary Leakage Symptoms
1 other identifier
interventional
19
1 country
1
Brief Summary
This was a single-center, open-label, single-arm, exploratory human study evaluating NatureU Pelvic Health Pumpkin Seed in adult women with urinary frequency and urinary leakage symptoms. Twenty-seven participants were recruited, 19 were screened and enrolled, and 19 completed the study and were included in the effectiveness analysis. Participants took the study product for 7 consecutive days, one tablet after lunch and one tablet after dinner, for a total daily intake of two tablets. Outcomes were assessed before product intake and after 7 days of use. The main outcomes included the Women Toileting Behavior Scale (WTBS) and the Incontinence Quality of Life questionnaire (I-QOL). Patient Global Impression of Improvement (PGI-I), waist circumference, fasting blood glucose, blood pressure, and safety observations were also assessed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 22, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 22, 2024
CompletedFirst Submitted
Initial submission to the registry
April 30, 2026
CompletedFirst Posted
Study publicly available on registry
May 6, 2026
CompletedMay 6, 2026
April 1, 2026
7 days
April 30, 2026
April 30, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change From Baseline in Women Toileting Behavior Scale Total Score
The Women Toileting Behavior Scale was used to assess urinary behavior. The primary endpoint was the within-participant change in WTBS total score from Day 0 to Day 8 after 7 days of product intake.
Baseline and Day 8 after 7 days of product intake
Secondary Outcomes (1)
Change From Baseline in Incontinence Quality of Life Total Score
Baseline and Day 8 after 7 days of product intake
Other Outcomes (2)
Patient Global Impression of Improvement
Day 8 after 7 days of product intake
Safety and Tolerability During Product Intake
Baseline through Day 8
Study Arms (1)
NatureU Pelvic Health Pumpkin Seed
EXPERIMENTALParticipants received NatureU Pelvic Health Pumpkin Seed, one tablet after lunch and one tablet after dinner each day for 7 consecutive days.
Interventions
NatureU Pelvic Health Pumpkin Seed is an oral functional food product containing pumpkin seed extract, soybean extract, vitamin D3, sorbitol, maltodextrin, microcrystalline cellulose, and magnesium stearate. Participants took one tablet after lunch and one tablet after dinner each day for 7 consecutive days.
Eligibility Criteria
You may qualify if:
- Participants who signed informed consent before the study and understood the study content, procedures, and possible adverse reactions.
- Adult women aged 35 to 55 years, inclusive, with urinary frequency and urinary leakage symptoms.
- Body weight at least 50 kg and body mass index between 18.5 and 23.9 kg/m2, inclusive.
- Participants able to maintain normal healthy routines and abstain from alcohol during the study period.
You may not qualify if:
- Pregnant or breastfeeding women, or women with recent pregnancy plans.
- Known allergy or hypersensitivity to product ingredients, including pumpkin or soybean, or a history of multiple food allergies.
- Diagnosed diabetes or other metabolic disease.
- Clinically significant abnormalities in blood glucose, blood pressure, physical examination, or vital signs as judged by the investigator.
- Acute or chronic inflammatory disease, including influenza A, within the previous month.
- Participation in any other clinical trial within 1 month before first use of the study product.
- Clinically significant disease within the previous 6 months judged by the investigator to make participation inappropriate.
- Acute illness or concomitant medication use from screening to first use of the study product.
- Surgery within the previous 3 months.
- Blood donation or major blood loss greater than 450 mL within the previous 3 months.
- Difficulty swallowing or a gastrointestinal disease history affecting product intake.
- Any disease that increases bleeding risk, such as hemorrhoids, acute gastritis, or gastric or duodenal ulcer.
- Use of prescription or non-prescription medications affecting nutritional supplements or hormone levels.
- Substantial weight change within the previous month.
- Any other factor judged by the investigator to make participation inappropriate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dao County People's Hospital
Yongzhou, Hunan, 425300, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Luke Law, Dr
OmniSolutions Laboratory Holdings Limited
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Masking Details
- The study was open-label with no masking.
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 30, 2026
First Posted
May 6, 2026
Study Start
July 15, 2024
Primary Completion
July 22, 2024
Study Completion
July 22, 2024
Last Updated
May 6, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to privacy protection and ethical considerations.